What does it mean when a stock is downgraded?

A downgrade is an analyst's opinion that the stock is likely to perform worse than previously expected, often leading to a lower rating (e.g., from "Buy" to "Hold" or "Sell").

What are upgrades in trading?

An upgrade is an analyst's opinion that the stock is likely to perform better than previously expected, often leading to a higher rating (e.g., from "Hold" to "Buy").

What is a downgrade list?

This is a list of stocks that have recently been downgraded by analysts.

Is it really a buy, sell, or hold?

These are common analyst ratings indicating their recommendation for the stock's future performance relative to the market or its sector.

What does a stock's rating of overweight mean?

"Overweight" (or "Buy") suggests the analyst believes the stock will outperform the average return of the stocks in the analyst's coverage universe or a relevant market index.

How reliable are analyst downgrades?

Analyst ratings are opinions and their reliability varies. Research the analyst's track record and the reasoning behind the downgrade.

How does downgrading work?

An analyst reviews a company's financials, industry trends, and other factors, and if their outlook becomes less positive, they issue a downgrade with a lower rating and potentially a lower price target.

What is the average return of an analyst?

Analyst performance is typically evaluated by the accuracy of their stock recommendations.

What is considered a downgrade?

A reduction in a stock's rating (e.g., Buy to Hold, Hold to Sell, Overweight to Neutral, Neutral to Underweight).

How does the stock market react to upgrade and downgrade?

Stock prices can move significantly on upgrades and downgrades, but the reaction depends on the analyst's reputation, the severity of the rating change, and overall market sentiment.

How can you tell what professional stock analysts recommend?

Financial news websites, brokerage platforms, and research providers often report on analyst ratings and recommendations.

What is the difference between downgrade and downsize?

A downgrade is an analyst's opinion on a stock. Downsize typically refers to a company reducing its workforce or operations.

What does downgrade candidate mean?

A stock that analysts believe is likely to be downgraded in the future based on negative trends or concerns.

What makes a stock a strong buy?

Strong buy ratings are typically given to stocks with compelling fundamentals, strong growth prospects, and analyst conviction of significant outperformance.

What does it mean when a stock is downgraded to neutral?

It means the analyst no longer recommends buying the stock but doesn't see a compelling reason to sell either, suggesting it will likely perform in line with the market or its sector.

What is the difference between downgrade and update?

A downgrade is a negative rating change. An update is a more general term for any revision or new information released by an analyst, which could include rating changes, price target adjustments, or commentary.

Stock Upgrades & Downgrades: Analyst Ratings & Trends

This page keeps you updated on the latest analyst revisions, highlighting stocks that are seeing positive or negative outlooks. These changes can help you spot new opportunities or potential risks. Our Analyst Screener helps you follow your preferred analysts, allowing you to see their ratings and track their past success, making it easier to align with expert opinions.

Symbol	Date	Firm	Analyst	Status	Price Target	Rating
BNED	Jun 26, 2026	Needham	Ryan MacDonald	Upgrade	16.0	Hold → Buy
FCEL	Jun 26, 2026	Jefferies	Dushyant Ailani	Upgrade	16.0 → 24.0	Hold → Buy
SYNA	Jun 26, 2026	Rosenblatt	Kevin Cassidy	Downgrade	180.0 → 160.0	Buy → Neutral
AMT	Jun 26, 2026	RBC Capital	Jonathan Atkin	Upgrade	195.0 → 205.0	Sector Perform → Outperform
CROX	Jun 26, 2026	Piper Sandler	Anna Andreeva	Upgrade	95.0 → 150.0	Neutral → Overweight
ESS	Jun 26, 2026	Raymond James	Buck Horne	Upgrade	320.0	Market Perform → Outperform
AVAV	Jun 26, 2026	Piper Sandler	Clarke Jeffries	Maintains	290.0 → 248.0	Overweight
KYMR	Jun 26, 2026	Canaccord Genuity	Edward Nash	Maintains	106.0 → 129.0	Buy
AMH	Jun 26, 2026	BMO Capital	Juan Sanabria	Upgrade	39.0	Market Perform → Outperform
FUL	Jun 26, 2026	JP Morgan	Jeffrey Zekauskas	Upgrade	58.0 → 67.0	Neutral → Overweight

65% OFFLIMITED TIME

Unlock Full Upgrades & Downgrades Screener

FREE Premium Picks ($208 value)

+137% vs S&P 500

3 Stocks Showing Early Price Action: P3 Health Partners (PIII), SINTX Technologies (SINT), Cardiol Therapeutics (CRDL)

The biotechnology sector remains an area of active interest for market participants seeking exposure to innovative therapies and emerging healthcare solutions. As companies progress through various stages of development, investors continue to evaluate clinical achievements, operational performance, and market positioning as key indicators of future potential. P3 Health Partners Inc (PIII) As of June 02, []

Jun 3, 2026

3 Stocks That Could See Trading Interest: Vivos Therapeutics (VVOS), Cardiol Therapeutics (CRDL), Dare Bioscience (DARE)

Healthcare and biotechnology stocks continue to attract investor attention as companies advance clinical programs, pursue regulatory milestones, and work toward commercial expansion. While market fluctuations remain common across the sector, developments related to product pipelines, financial performance, and strategic initiatives often play a significant role in shaping investor sentiment and long-term growth expectations. Vivos Therapeutics []

Jun 3, 2026

3 Stocks That Could Get Active: Cardiol Therapeutics (CRDL), Silexion Therapeutics (SLXN), Can-Fite Biopharma (CANF)

Investors continue to monitor emerging biotechnology companies as clinical development milestones, financial performance, and market activity shape sentiment across the healthcare sector. While development-stage biotech firms often experience significant share-price volatility, advancements in clinical programs, regulatory progress, and commercial potential remain key factors influencing long-term valuation. The following companies have recently attracted attention as they []

Jun 3, 2026

3 Stocks Showing Steady Interest: PharmaCyte Biotech (PMCB), Cardiol Therapeutics (CRDL), Processa Pharmaceuticals (PCSA)

The healthcare sector remains one of the most closely watched areas of the market, with investors seeking companies capable of delivering meaningful innovation and long-term growth. From late-stage clinical developments to improving operational performance, a number of healthcare-focused firms are positioning themselves for potentially significant milestones that could shape their trajectories in the months ahead. []

Jun 2, 2026

3 Stocks That Could Attract Market Eyes: Cardiol Therapeutics (CRDL), Nasus Pharma (NSRX), Intensity Therapeutics (INTS)

Biotechnology and healthcare stocks remain active areas of investor focus as advancements in medical research, diagnostics, and therapeutic development continue to reshape the industry landscape. Companies progressing through key development stages or demonstrating improving business fundamentals are increasingly being evaluated for their ability to generate long-term value in a competitive market environment. Cardiol Therapeutics Inc. []

Jun 2, 2026

3 Stocks Worth Keeping Track Of: ENvue Medical (FEED), FocalTherics (FOCL), Cardiol Therapeutics (CRDL)

As investors search for opportunities beyond large-cap pharmaceutical companies, attention continues to shift toward smaller healthcare and biotechnology firms with promising pipelines and evolving business strategies. These companies often present higher risk profiles, but successful execution of clinical, operational, or commercial objectives can create substantial upside potential for shareholders. ENvue Medical Inc (FEED) ENvue Medical []

Jun 2, 2026

3 Stocks Worth Watching for Changes: Adagio Medical (ADGM), American Shared Hospital Services (AMS), Cardiol Therapeutics (CRDL)

Small-cap biotech stocks frequently offer a unique combination of risk and reward, particularly when companies are advancing promising therapies through the clinical development process. While uncertainty remains inherent in drug development, successful trial outcomes and regulatory progress can create substantial shareholder value. Against this backdrop, several healthcare companies are drawing attention for their scientific programs, []

Jun 1, 2026

3 Stocks That Could Draw Buyers: IRIDEX (IRIX), Cardiol Therapeutics (CRDL), Elutia (ELUT)

Healthcare innovation remains one of the most dynamic segments of the market, with clinical-stage biotechnology companies pursuing new treatments that could address significant unmet medical needs. As investors search for emerging opportunities, attention often shifts toward companies approaching critical development milestones, where clinical data, regulatory interactions, and commercialization strategies can have a meaningful impact on []

Jun 1, 2026

3 Stocks Showing Positive Trends: Cardiol Therapeutics (CRDL), FibroBiologics (FBLG), Scienture (SCNX)

The biotechnology sector continues to attract investor attention as companies advance innovative therapies across multiple disease areas and move closer to key clinical and commercial milestones. While market volatility remains a defining characteristic of emerging healthcare stocks, firms with differentiated technologies, strong development pipelines, and upcoming catalysts are increasingly being monitored by investors seeking long-term []

Jun 1, 2026

Upgrades and Downgrades

Unlock Full Upgrades & Downgrades Screener

Must Read

Visteon Corporation (VC) Receives Neutral Rating from Baird With Price Target of $121

Tango Therapeutics, Inc. (TNGX): Analysts Signal Opportunity with New Buy Rating and Significant Upside Potential

Trip.com Group Limited (TCOM) Receives Neutral Rating from Macquarie: Potential Upside Persists

Synaptics Incorporated (SYNA): Neutral Rating Implies Limited Upside Ahead

Spire Inc. (SR) Receives Neutral Rating from JP Morgan Amid Steady Performance

Methode Electronics, Inc. (MEI): Neutral Rating Implies Limited Upside Amid Looming Challenges

The Macerich Company (MAC): Neutral Rating Signals Caution as Stock Stalls Below Average Price Target

Open Lending Corporation (LPRO) Receives Neutral Rating Amidst Modest Price Target Rise

Frequency Asked Questions